Articles

P.14.2 KIT D816 mutation in myeloid neoplasms: look out for systemic mastocytosis associated hematologic neoplasms (SM-AHN)

BJH - volume 11, issue Abstract Book BHS, february 2020

E. Linskens , S. Van Landeghem , K. Vandepoele PhD, K. Maes , I. Moors MD, J. Van Dorpe , C. Bonroy , K. Devreese , J. Philippé MD, PhD, B. Denys PharmD

Read more

PP.01 The role of the de novo DNA methyltransferase DNMT3B in multiple myeloma cell survival and drug resistance

BJH - volume 11, issue Abstract Book BHS, february 2020

C. Muylaert , E. De Bruyne , P. Vlummens MD, K. Maes , K. De Veirman , E. Menu , K. Vanderkerken PhD

Read more

O.2 AXL: A potential therapeutic target to eliminate cancer cells and improve chemotherapeutic responses in different hematological cancers

BJH - volume 11, issue Abstract Book BHS, february 2020

N. Vandewalle , P. Vlummens MD, N. De Beule , S. Faict , I. Oudaert , K. Maes , E. De Bruyne , E. Menu , K. Vanderkerken PhD, K. De Veirman

Read more

P15 Chronic myeloid leukemia initially presenting with acute haemopericardium and cardiac tamponade: case presentation and identification of a possible pitfall

BJH - 2018, issue Abstract Book BHS, february 2018

K. Maes , K. Imaeva , E. Steel , T. Kerre MD, PhD, P. Vlummens MD

Read more

O5 Inhibition of multiple myeloma exosomes prevents bone loss and reduces tumor growth.

BJH - 2018, issue Abstract Book BHS, february 2018

S. Faict , K. De Veirman , K. Maes , E. De Bruyne , H. Schots , R. Heusschen PhD, J. Caers MD, PhD, K. Vanderkerken PhD, E. Menu

Read more

P08 Immunotherapy in Multiple Myeloma using alfa-galactosylceramide loaded sEVs from dendritic cells to stimulate NKT activity

BJH - volume 8, issue Abstract Book BHS, february 2017

S. Faict , M. Favreau , E.D.B. E. , K. De Veirman , K. Maes , K. Vanderkerken PhD, R. Schots MD, PhD, E. Menu

Read more